INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84501, 'Erythromycin', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84602/', '', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, More', 'Ciclesonide, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, Mometasone furoate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84502, 'Exenatide', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84603/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84503, 'Fedratinib', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84604/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84504, 'Flurbiprofen (ophthalmic)', 'Dexamethasone (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84605/', '', 'Rabeprazole, Phenylbutazone, Indomethacin, Tolazoline, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84505, 'Glimepiride', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84606/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84506, 'Glipizide', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84607/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Olopatadine, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84507, 'Glyburide', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84608/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Olopatadine, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84508, 'Idelalisib', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84609/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84509, 'Indinavir', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84610/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84510, 'Insulin human', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84611/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84511, 'Insulin aspart (aspart)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84612/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84512, 'Insulin aspart (aspart protamine)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84613/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84513, 'Insulin degludec', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84614/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84514, 'Insulin detemir', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84615/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84515, 'Insulin glargine', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84616/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84516, 'Insulin glulisine', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84617/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84517, 'Insulin human (inhalation, rapid acting)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84618/', '', 'Mupirocin, Vitamin A, Olopatadine, Hyaluronic acid, Azelastine, Fluorometholone, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84518, 'Insulin human (isophane)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84619/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84519, 'Insulin lispro', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84620/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84520, 'Insulin lispro (protamine)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84621/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84521, 'Insulin human (regular)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84622/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84522, 'Insulin human (zinc)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84623/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84523, 'Insulin human (zinc extended)', 'Dexamethasone (ophthalmic)', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84624/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84524, 'Itraconazole', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84625/', '', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84525, 'Dexamethasone (ophthalmic)', 'Ketoconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84626/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84526, 'Dexamethasone (ophthalmic)', 'Linagliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84627/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84527, 'Dexamethasone (ophthalmic)', 'Liraglutide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84628/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84528, 'Dexamethasone (ophthalmic)', 'Lixisenatide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84629/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84529, 'Dexamethasone (ophthalmic)', 'Lonafarnib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84630/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84530, 'Dexamethasone (ophthalmic)', 'Miconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84631/', '', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84531, 'Dexamethasone (ophthalmic)', 'Miglitol', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84632/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84532, 'Dexamethasone (ophthalmic)', 'Nateglinide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84633/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84533, 'Dexamethasone (ophthalmic)', 'Nefazodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84634/', '', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84534, 'Dexamethasone (ophthalmic)', 'Nelfinavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84635/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84535, 'Dexamethasone (ophthalmic)', 'Nepafenac (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84636/', '', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84536, 'Dexamethasone (ophthalmic)', 'Pioglitazone', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84637/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mometasone, Flunisolide, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Azelastine, Beclomethasone dipropionate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84537, 'Dexamethasone (ophthalmic)', 'Posaconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84638/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84538, 'Dexamethasone (ophthalmic)', 'Pramlintide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84639/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84539, 'Dexamethasone (ophthalmic)', 'Repaglinide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84640/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84540, 'Dexamethasone (ophthalmic)', 'Ritonavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84641/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84541, 'Dexamethasone (ophthalmic)', 'Rosiglitazone', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84642/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Beclomethasone dipropionate, Fluorometholone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84542, 'Dexamethasone (ophthalmic)', 'Saquinavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84643/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84543, 'Dexamethasone (ophthalmic)', 'Saxagliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84644/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84544, 'Dexamethasone (ophthalmic)', 'Semaglutide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84645/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84545, 'Dexamethasone (ophthalmic)', 'Sitagliptin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84646/', '', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84546, 'Dexamethasone (ophthalmic)', 'Smallpox (Vaccinia) Vaccine, Live', 'Major', 'The administration of live virus smallpox vaccine during corticosteroid therapy may be associated with a risk of localized or disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients receiving high dosages of systemic corticosteroids and those who are systemically immunosuppressed due to long-term topical or aerosol use of corticosteroids may also have an increased risk of neurologic reactions to vaccines and decreased or suboptimal immunologic response due to antibody inhibition. The risk of ocular complications may be increased in patients who are using ophthalmic corticosteroids.', 'DDInter', 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored. The interval depends on the dosage, duration, and route of corticosteroid therapy administered, but may be at least 3 months in most cases of systemic corticosteroid use. In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks. Household contacts of immunosuppressed patients should also not be vaccinated. However, there are no absolute contraindications to vaccination if a high-risk exposure has occurred. In an outbreak emergency, smallpox vaccine is generally recommended for all persons, regardless of medical conditions. The risk for experiencing serious complications from the vaccine should be weighed against the risk of acquiring a potentially fatal smallpox infection. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84647/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84547, 'Dexamethasone (ophthalmic)', 'Suprofen (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84648/', '', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84548, 'Dexamethasone (ophthalmic)', 'Telaprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84649/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84549, 'Dexamethasone (ophthalmic)', 'Telithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84650/', '', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', 'Mupirocin, Mometasone furoate, Epinephrine, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84550, 'Dexamethasone (ophthalmic)', 'Tolazamide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84651/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84551, 'Dexamethasone (ophthalmic)', 'Tolbutamide', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84652/', '', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84552, 'Dexamethasone (ophthalmic)', 'Troglitazone', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by concomitant use of ophthalmic corticosteroids, particularly during prolonged use. Corticosteroids can raise blood glucose levels by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Corticosteroids may interfere with blood glucose control and may cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Systemic absorption from use of ophthalmic corticosteroids may occur. Clinical monitoring of glycemic control is recommended if ophthalmic corticosteroids are administered to diabetic patients.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84653/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84553, 'Dexamethasone (ophthalmic)', 'Troleandomycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84654/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84554, 'Dexamethasone (ophthalmic)', 'Tucatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84655/', '', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84555, 'Dexamethasone (ophthalmic)', 'Voriconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84656/', '', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84556, 'Dexamethasone (ophthalmic)', 'Voxelotor', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84657/', '', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84557, 'Aluminum hydroxide', 'Dextroamphetamine', 'Moderate', 'Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.', 'DDInter', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.', 'Absorption', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84658/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84558, 'Ammonium chloride', 'Dextroamphetamine', 'Moderate', 'Urinary acidifying agents such as ammonium chloride, sodium acid phosphate, and methenamine salts may lower the blood levels and efficacy of amphetamines. Acidifying the urine has been reported to increase the concentration of the ionized species of the amphetamine molecule, thereby inhibiting renal tubular absorption and increasing its urinary excretion.', 'DDInter', 'Patients receiving an amphetamine in combination with urinary acidifying agents should be monitored for potentially diminished pharmacologic response to the amphetamine.', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84659/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Darifenacin, Vardenafil, Tadalafil, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84559, 'Amoxapine', 'Dextroamphetamine', 'Moderate', 'The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.', 'DDInter', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.', 'Metabolism, Synergism', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84660/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Pemoline, Metamfetamine, Solriamfetol, Caffeine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84560, 'Dextroamphetamine', 'Calcium carbonate', 'Moderate', 'Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.', 'DDInter', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.', 'Absorption', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84661/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Calcium Phosphate, Calcium chloride, Calcium acetate, Calcium citrate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84561, 'Dextroamphetamine', 'Chlorpromazine', 'Moderate', 'Phenothiazines may antagonize the pharmacologic effects of amphetamine, amphetamine derivatives, and other centrally-acting sympathomimetic agents (i.e., CNS stimulants). Conversely, these agents may diminish the neuroleptic efficacy of phenothiazines. The exact mechanism of interaction is unknown but may involve opposing effects on dopaminergic activity.', 'DDInter', 'Amphetamine, amphetamine derivatives, and other CNS stimulants should generally not be used, particularly for weight reduction, in patients treated with phenothiazines.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84662/', '', 'Thiothixene, Risperidone, Amisulpride, Quetiapine, Lumateperone, Cariprazine, Paliperidone, Lurasidone, Pimavanserin, Clozapine, Asenapine, More', 'Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84562, 'Dextroamphetamine', 'Cocaine (nasal)', 'Major', 'Concomitant use of cocaine with sympathomimetic agents such as epinephrine and phenylephrine may lead to additive cardiovascular effects. The proposed mechanism involves increased circulating catecholamines and increased activity of the sympathetic nervous system.', 'DDInter', 'Concomitant use of cocaine with sympathomimetic agents should be avoided. If coadministration is required, prolonged vital sign and ECG monitoring may be necessary.', 'Synergism', 'Concomitant use of cocaine with sympathomimetic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84663/', '', 'Citicoline, Solriamfetol', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84563, 'Didanosine', 'Dextroamphetamine', 'Moderate', 'Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.', 'DDInter', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.', 'Absorption', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84664/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84564, 'Dobutamine', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84665/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84565, 'Dopamine', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84666/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84566, 'Doxepin', 'Dextroamphetamine', 'Moderate', 'The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.', 'DDInter', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.', 'Metabolism, Synergism', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84667/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Lidocaine, Clemastine, Tetracaine, More', 'Pemoline, Metamfetamine, Solriamfetol, Caffeine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84567, 'Doxepin (topical)', 'Dextroamphetamine', 'Moderate', 'The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.', 'DDInter', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.', 'Metabolism, Synergism', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84668/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Lidocaine, Clemastine, Tetracaine, More', 'Pemoline, Atomoxetine, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84568, 'Droxidopa', 'Dextroamphetamine', 'Moderate', 'Agents that increase blood pressure such as vasopressors, triptans, decongestants, beta-2 agonists, and amphetamines may potentiate the risk of supine hypertension associated with the use of droxidopa in the treatment of neurogenic orthostatic hypotension.', 'DDInter', 'Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage. Patients should elevate the head of the bed when resting or sleeping, and have blood pressure also measured in this position. Dosage reduction or discontinuation of droxidopa is recommended if supine hypertension cannot be managed by elevation of the head of the bed. Supine hypertension that is not well managed may increase the risk of cardiovascular events, particularly stroke.', 'Synergism', 'Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84669/', '', 'Pemoline, Atomoxetine, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84569, 'Duloxetine', 'Dextroamphetamine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', 'DDInter', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84670/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Armodafinil, Dexmethylphenidate, Pemoline, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84570, 'Ephedrine', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84671/', '', 'Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, More', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84571, 'Escitalopram', 'Dextroamphetamine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', 'DDInter', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84672/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Pemoline, Solriamfetol, Caffeine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84572, 'Esketamine', 'Dextroamphetamine', 'Major', 'Coadministration with psychostimulants (e.g., amphetamines) or monoamine oxidase inhibitors (MAOIs) may potentiate the hypertensive effects of esketamine.', 'DDInter', 'Caution is advised and blood pressure should be closely monitored during concomitant use of esketamine with psychostimulants or MAOIs. All patients receiving esketamine should have BP assessed prior to administration. If BP is elevated (e.g., >140 mmHg systolic, >90 mmHg diastolic), a delay in esketamine treatment may be necessary, taking into consideration the benefits versus risks in individual patients. BP should be monitored for at least 2 hours after esketamine administration, starting at approximately 40 minutes post-dose and subsequently as clinically warranted. In patients with a history of hypertensive encephalopathy, more intensive monitoring is warranted due to increased risk for developing encephalopathy with even small increases in BP. If at any point BP is elevated and remains high, promptly seek assistance from practitioners experienced in BP management. Patients experiencing symptoms of a hypertensive crisis (e.g., chest pain, shortness of breath) or hypertensive encephalopathy (e.g., sudden severe headache, visual disturbances, seizures, diminished consciousness or focal neurological deficits) should be immediately referred for emergency care.', 'Synergism', 'Caution is advised and blood pressure should be closely monitored during concomitant use of esketamine with psychostimulants or MAOIs.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84673/', '', 'Citicoline, Solriamfetol', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Halothane, Thiopental, Sodium oxybate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84573, 'Ethosuximide', 'Dextroamphetamine', 'Minor', 'Amphetamines may delay the intestinal absorption of ethosuximide, phenobarbital, and phenytoin. The mechanism of interaction and clinical significance are unknown.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84674/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', 'Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84574, 'Fenfluramine', 'Dextroamphetamine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', 'DDInter', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84675/', '', 'Naltrexone, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, More', 'Pemoline, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84575, 'Fluoxetine', 'Dextroamphetamine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', 'DDInter', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84676/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Pemoline, Solriamfetol, Caffeine, Armodafinil, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84576, 'Fluphenazine', 'Dextroamphetamine', 'Moderate', 'Phenothiazines may antagonize the pharmacologic effects of amphetamine, amphetamine derivatives, and other centrally-acting sympathomimetic agents (i.e., CNS stimulants). Conversely, these agents may diminish the neuroleptic efficacy of phenothiazines. The exact mechanism of interaction is unknown but may involve opposing effects on dopaminergic activity.', 'DDInter', 'Amphetamine, amphetamine derivatives, and other CNS stimulants should generally not be used, particularly for weight reduction, in patients treated with phenothiazines.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84677/', '', 'Thiothixene, Risperidone, Amisulpride, Quetiapine, Lumateperone, Cariprazine, Paliperidone, Lurasidone, Pimavanserin, Clozapine, Asenapine, More', 'Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84577, 'Ginkgo biloba', 'Dextroamphetamine', 'Moderate', 'Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4''-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4''-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.', 'DDInter', 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4''-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.', 'Synergism', 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84678/', '', 'Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab', 'Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84578, 'Glutamic acid', 'Dextroamphetamine', 'Moderate', 'Gastrointestinal acidifying agents such as glutamic acid HCl and ascorbic acid may lower the blood levels and efficacy of amphetamines.', 'DDInter', 'Patients receiving an amphetamine in combination with gastrointestinal acidifying agents should be monitored for potentially diminished pharmacologic response to the amphetamine.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84679/', '', 'Citric acid, Pancrelipase', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84579, 'Glycerol phenylbutyrate', 'Dextroamphetamine', 'Moderate', 'Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.', 'DDInter', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.', 'Metabolism', 'Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84680/', '', 'Pemoline, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84580, 'Guanadrel', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings. CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.', 'DDInter', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants. If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84681/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84581, 'Guanethidine', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings. CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.', 'DDInter', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants. If the combination is used, blood pressure and heart rate should be monitored.', 'Antagonism', 'Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84682/', '', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, More', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84582, 'Haloperidol', 'Dextroamphetamine', 'Moderate', 'Butyrophenone neuroleptics may antagonize the pharmacologic effects of amphetamine, amphetamine derivatives, and other centrally-acting sympathomimetic agents (i.e., CNS stimulants). Conversely, these agents may diminish the neuroleptic efficacy of butyrophenones. The exact mechanism of interaction is unknown but may involve opposing effects on dopaminergic activity.', 'DDInter', 'Amphetamine, amphetamine derivatives, and other CNS stimulants should generally not be used, particularly for weight reduction, in patients treated with a butyrophenone neuroleptic agent.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84683/', '', 'Thiothixene, Risperidone, Amisulpride, Quetiapine, Lumateperone, Cariprazine, Paliperidone, Lurasidone, Pimavanserin, Clozapine, Asenapine, More', 'Citicoline, Solriamfetol, Caffeine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84583, 'Imipramine', 'Dextroamphetamine', 'Moderate', 'The use of tricyclic antidepressants in combination with amphetamines or sympathomimetic appetite suppressants may produce additive cardiovascular effects, increasing the risk of hypertension, cardiac arrhythmias, tachycardia, and fever. The mechanism involves additive pharmacodynamic effects resulting from increased norepinephrine release by sympathomimetic agents and inhibition of norepinephrine reuptake by tricyclic antidepressants. A pharmacokinetic interaction is also possible between tricyclic antidepressants and amphetamines, since many of these agents are metabolized by CYP450 2D6. Increased plasma levels of one or both drugs may occur during coadministration.', 'DDInter', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination. Patients should be advised to promptly report symptoms such as fever, headache, or fast or irregular heartbeats.', 'Metabolism, Synergism', 'Close monitoring of cardiovascular status is recommended for patients receiving this combination.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84684/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Pemoline, Metamfetamine, Solriamfetol, Caffeine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84584, 'Indacaterol', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84685/', '', 'Pemoline, Citicoline, Caffeine', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84585, 'Iobenguane (I-131)', 'Dextroamphetamine', 'Major', 'Coadministration with drugs that reduce catecholamine uptake or deplete catecholamine stores may interfere with iobenguane I-131 uptake into neuroendocrine tumors such as pheochromocytoma and paraganglioma that express high levels of norepinephrine transporter on their cell surfaces. Since iobenguane is similar in structure to norepinephrine and is subject to the same uptake and accumulation pathways as norepinephrine, drugs that alter norepinephrine disposition in adrenergic nerve terminals and presynaptic storage vesicles will likewise affect iobenguane.', 'DDInter', 'Drugs that reduce catecholamine uptake or deplete catecholamine stores should be discontinued for at least five biological half-lives before administration of either the dosimetry dose or a therapeutic dose of iobenguane I-131. Do not administer these drugs until at least 7 days after each iobenguane I-131 dose. Patients should be monitored for the occurrence of clinically significant withdrawal symptoms, especially patients with elevated levels of circulating catecholamines and their metabolites.', 'Distribution', 'Drugs that reduce catecholamine uptake or deplete catecholamine stores should be discontinued for at least five biological half-lives before administration of either the dosimetry dose or a therapeutic dose of iobenguane I-131.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84686/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84586, 'Isocarboxazid', 'Dextroamphetamine', 'Major', 'Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.', 'DDInter', 'In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).', 'Synergism', 'In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84687/', '', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84587, 'Isoetharine', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84688/', '', 'Pemoline, Citicoline, Caffeine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84588, 'Isoprenaline', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84689/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Pemoline, Citicoline, Caffeine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84589, 'Dextroamphetamine', 'Levosalbutamol', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84690/', '', 'Pemoline, Citicoline, Caffeine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84590, 'Dextroamphetamine', 'Levomilnacipran', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', 'DDInter', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84691/', '', 'Pemoline, Atomoxetine, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84591, 'Dextroamphetamine', 'Levothyroxine', 'Moderate', 'The concomitant use of thyroid hormones, especially large doses, with sympathomimetic drugs may potentiate sympathomimetic effects and increase the risk of cardiac insufficiency in patients who have coronary artery disease.', 'DDInter', 'Monitoring for increased sympathomimetic effects and cardiac function may be advisable.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84692/', '', 'Solriamfetol, Caffeine, Dexmethylphenidate, Armodafinil, Citicoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84592, 'Dextroamphetamine', 'Lindane', 'Moderate', 'Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).', 'DDInter', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.', 'Synergism', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84693/', '', 'Disulfiram', 'Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84593, 'Dextroamphetamine', 'Linezolid', 'Major', 'Centrally-acting sympathomimetic agents (i.e., CNS stimulants), particularly the amphetamines and amphetamine derivatives, may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). MAOIs also slow amphetamine metabolism, which may potentiate amphetamine effect on the release of norepinephrine and other monoamines from adrenergic nerve endings.', 'DDInter', 'In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).', 'Synergism', 'In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84694/', '', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Spectinomycin, Lefamulin, Nitrofurantoin, More', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84594, 'Dextroamphetamine', 'Liothyronine', 'Moderate', 'The concomitant use of thyroid hormones, especially large doses, with sympathomimetic drugs may potentiate sympathomimetic effects and increase the risk of cardiac insufficiency in patients who have coronary artery disease.', 'DDInter', 'Monitoring for increased sympathomimetic effects and cardiac function may be advisable.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84695/', '', 'Pemoline, Solriamfetol, Caffeine, Dexmethylphenidate, Armodafinil, Citicoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84595, 'Dextroamphetamine', 'Lithium carbonate', 'Minor', 'The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate. The mechanism of interaction is unknown. Clinicians prescribing the combination should be aware of this potential interaction.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84696/', '', 'Pemoline, Solriamfetol, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84596, 'Dextroamphetamine', 'Magnesium carbonate', 'Moderate', 'Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.', 'DDInter', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.', 'Absorption', 'Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84697/', '', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84597, 'Dextroamphetamine', 'Meperidine', 'Moderate', 'Coadministration of amphetamines and amphetamine-like drugs with certain opioids or the synthetic opioid derivative, dextromethorphan, may increase the risk of serotonin syndrome. Dextromethorphan and some opioids, particularly those in the phenylpiperidine class, are weak serotonin reuptake inhibitors whose effects may be potentiated by amphetamines.', 'DDInter', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol. Patients should be monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Caution is recommended when amphetamines and amphetamine-like drugs are used with dextromethorphan or opioids with serotonergic effects such as fentanyl, meperidine, methadone, propoxyphene, and tramadol.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84698/', '', 'Oliceridine, Morphine, Naltrexone, Oxymorphone, Naloxone, Oxycodone, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, More', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84598, 'Dextroamphetamine', 'Mephentermine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84699/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84599, 'Dextroamphetamine', 'Mesoridazine', 'Moderate', 'Phenothiazines may antagonize the pharmacologic effects of amphetamine, amphetamine derivatives, and other centrally-acting sympathomimetic agents (i.e., CNS stimulants). Conversely, these agents may diminish the neuroleptic efficacy of phenothiazines. The exact mechanism of interaction is unknown but may involve opposing effects on dopaminergic activity.', 'DDInter', 'Amphetamine, amphetamine derivatives, and other CNS stimulants should generally not be used, particularly for weight reduction, in patients treated with phenothiazines.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84700/', '', 'Thiothixene, Risperidone, Amisulpride, Quetiapine, Lumateperone, Cariprazine, Paliperidone, Lurasidone, Pimavanserin, Clozapine, Asenapine, More', 'Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (84600, 'Dextroamphetamine', 'Orciprenaline', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/84701/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Pemoline, Citicoline, Caffeine', 1767369485);
